Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- The hypolipemic properties of 2-acetoamidoethyl (p-chlorophenyl) (m-trifluoromethylphenoxy) acetate in the rat.in: 4th edition. Proc. Soc. Exp. Biol. Med.136. 1971: 1274-1276
- The effect of MK-185 on some aspects of uric acid metabolism.Clin. Pharmacol. Therap. 1970; 11: 551-557
- Clinical evaluation of MK-185; a new hypolipidemic drug.J. Amer. Oil Chemists Soc. 1971; 48: 92A
- Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate).Clin. Pharmacol. Therap. 1971; 12: 517-524
- Multiple range and multiple F test.Biometrics. March, 1955;
- Alteration of factors predisposing to coronary heart disease.Ann. Intern. Med. 1968; 68: 1072-1077
Hutchison, J. C., and Wilkinson, W. H., The dosage, form and mg/K response of halofenate (MK-185) on uric acid and serum lipids, To be published.
- Metabolism of a new hypolipidemic agent, 2-acetamidoethyl (p-chlorophenyl) (m-trifluormethylphenoxy) acetate (halofenate) in the rat, dog, rhesus monkey and man.J. Pharmacol. Exp. Therap. 1971; 179: 359